10X Genomics Stock Hits Day Low of $18.80 Amid Price Pressure

10X Genomics, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable decline today, with its stock price dropping by 7.43% as of March 12, 2026. The stock reached an intraday low of USD 18.80, reflecting a challenging trading session. In terms of performance metrics, 10X Genomics has shown a mixed trend over various time frames. Over the past week, the stock has decreased by 12.48%, while it has gained 8.17% over the past month. Year-to-date, the stock has performed positively, with a return of 16.13%, significantly outpacing the S&P 500, which has seen a decline of 2.53% in the same period. However, the three-year and five-year performance remains concerning, with declines of 57.91% and 88.16%, respectively. The company maintains a high institutional ownership at 100%, indicating strong backing from institutional investors. Despite the recent downturn, 10X Genomics has generated a substantial return of 89.27% over the last year, outperforming the broader market.